• 1
    Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997; 25: 18131819.
  • 2
    Svoboda P, Kantorova I, Ochmann J. Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma 1994; 36: 336340.
  • 3
    Cryer HG, Leong K, McArthur DL, Demetriades D, Bongard FS, Fleming AW, et al. Multiple organ failure: by the time you predict it, it's already there. J Trauma 1999; 46: 597604.
  • 4
    Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999; 82: 298304.
  • 5
    Meng ZH, Dyer K, Billiar TR, Tweardy DJ. Essential role for IL-6 in postresuscitation inflammation in hemorrhagic shock. Am J Physiol Cell Physiol 2001; 280: C343C351.
  • 6
    Yang R, Han X, Uchiyama T, Watkins SK, Yaguchi A, Delude RL, et al. IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol 2003; 285: G621G629.
  • 7
    Harrington CA, Rosenow C, Retief J. Monitoring gene expression using DNA microarrays. Curr Opin Microbiol 2002; 3: 285291.
  • 8
    Alam HB, Stegalkina S, Rhee P, Koustova E. cDNA array analysis of gene expression following hemorrhagic shock and resuscitation in rats. Resuscitation 2002; 54: 195206.
  • 9
    Kjoller L, Kanse SE, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420429.
  • 10
    Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100: 5867.
  • 11
    Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781791.
  • 12
    Mars WM, Kim T-H, Stolz DB, Liu M-L, Michalopoulos GK. The presence of urokinase in serum-free, primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Cancer Res 1996; 56: 28372843.
  • 13
    Yamashita M, Darlington DN, Weeks EJ, Jones RO, Gann DS. Plasminogen activator inhibitor-1 rises after hemorrhage in rats. Am J Physiol Endocrinol Metab 1995; 268: E1065E1069.
  • 14
    Yamashita M, Darlington DN, Imafuku S, Gann DS. Plasminogen activator inhibitor-1 mRNA is induced by hemorrhage in endothelial and mesothelial cells of the rat liver. Thromb Haemost 1995; 74: 933937.
  • 15
    Hua Y, Xi G, Keep RF, Wu J, Jiang Y, Hoff JT. Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2002; 22: 5561.
  • 16
    Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 27462755.
  • 17
    Ma Z, Thomas KS, Webb DJ, Moravec R, Salicioni AM, Mars WM, et al. Regulation of Rac1 activation by the low density lipoprotein receptor-related protein. J Cell Biol 2002; 159: 10611070.
  • 18
    Wack KE, Ross MA, Zegarra V, Sysko LR, Watkins SC, Stolz DB. Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. HEPATOLOGY 2001; 33: 363378.
  • 19
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680685.
  • 20
    Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110: 15251538.
  • 21
    Watanabe K, Tanaka K. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells. Atherosclerosis 1983; 48: 5770.
  • 22
    Chen JP, Rowe DW, Enderson BL. Contrasting post-traumatic serial changes for D-dimer and PAI-1 in critically injured patients. Thromb Res 1999; 94: 175185.
  • 23
    Kim T-H, Mars WM, Stolz DB, Petersen BE, Michalopoulos GK. Extracellular matrix remodeling at the early stages of liver regeneration in the rat. HEPATOLOGY 1997; 26: 896904.
  • 24
    Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 1995; 23: 18351842.
  • 25
    Naka T, Nishimotov N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4(Suppl 3): S233S242.
  • 26
    Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003; 112: 978980.
  • 27
    Okada K, Fujita T, Minamoto K, Liao H, Naka Y, Pinsky DJ. Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice. J Biol Chem 2000; 275: 2146821476.
  • 28
    Karakozis S, Hinds M, Cook JW, Kim D, Provido H, Kirkpatrick JR. The effects of interleukin-10 in hemorrhagic shock. J Surg Res 2000; 90: 109112.
  • 29
    Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001; 158: 11111120.
  • 30
    Lecouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299: 890893.
  • 31
    Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143: 949958.
  • 32
    Bissell DM. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med 2001; 33: 179190.
  • 33
    Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS 1999; 107: 8085.
  • 34
    Inoue K, Sugawara Y, Kubota K, Takayama T, Makuuchi M. Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion. J Hepatol 2000; 33: 407414.
  • 35
    Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285: L20L28.
  • 36
    Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 22412247.
  • 37
    Trifiletti A, Scamardi R, Pizzoleo MA, Soraci S, Nevoso A, Bagnato L, et al. Haemostatic changes in patients with deep vein thrombosis. Panminerva Med 1997; 39: 2123.
  • 38
    Watanabe Y, Takahashi H, Uno S, Takano S, Nakagawa S. Expression of type 1 plasminogen activator inhibitor and nitric oxide generation in ischemic preconditioning of rat liver. Hepatol Res 2003; 25: 343353.
  • 39
    Okajima K, Harada N, Kushimoto S, Uchiba M. Role of microthrombus formation in the development of ischemia/reperfusion-induced liver injury in rats. Thromb Haemost 2002; 88: 473480.
  • 40
    Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992; 11: 48254833.
  • 41
    Copple BL, Woolley B, Banes A, Ganey PE, Roth RA. Anticoagulants prevent monocrotaline-induced hepatic parenchymal cell injury but not endothelial cell injury in the rat. Toxicol Appl Pharmacol 2002; 180: 186196.
  • 42
    Mars WM, Liu ML, Kitson RP, Goldfarb RH, Gabauer MK, Michalopoulos GK. Immediate early detection of urokinase receptor after partial hepatectomy. HEPATOLOGY 1995; 21: 16951701.
  • 43
    Pohl JF, Melin-Aldana H, Sabla G, Degen JL, Bezerra JA. Plasminogen deficiency leads to impaired lobular reorganization and matrix accumulation after chronic liver injury. Am J Pathol 2001; 159: 21792186.
  • 44
    Shimizu M, Hara A, Okuno M, Matsuno H, Okada K, Ueshima S, et al. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. HEPATOLOGY 2001; 33: 569576.
  • 45
    Sakakura Y, Kaibori M, Oda M, Okumura T, Kwon AH, Kamiyama Y. Recombinant human hepatocyte growth factor protects the liver against hepatic ischemia and reperfusion injury in rats. J Surg Res 2000; 92: 261266.
  • 46
    Bustos M, Beraza N, Lasarte JJ, Baixeras E, Alzuguren P, Bordet T, et al. Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. Gastroenterology 2003; 125: 192201.
  • 47
    Chen L, Zeng Y, Yang H, Lee TD, French SW, Corrales FJ, et al. Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A. FASEB J 2004; 18: 914916.
  • 48
    Menges T, Hermans PW, Little SG, Langefeld T, Boning O, Engel J, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357: 10961097.